Bendamustine Hydrochloride for the Treatment of Relapsed or Refractory Acute Leukemia

Study Title
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Teva Identifier
C18083/2046 | 2010-020768-40
ClinicalTrials.gov Identifier
NCT01088984
Study Status
Completed
Trial Condition(s)
Leukemia
Interventions
Drug: Bendamustine

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Child, Adult
Age Range
1 Year to 20 Years
Trial Duration
08/01/2010 - 08/01/2011
Phase
Phase 1/2

Study Type

Interventional